Literature DB >> 34405773

Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Jérémie Zerbit1, Jerome Tamburini2, Lauriane Goldwirt3, Justine Decroocq3, Jean Michel Cayuela4, Nicolas Chapuis5, Adrien Contejean2, Rui Batista1, Didier Bouscary3, Lise Willems3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34405773     DOI： 10.1080/10428194.2021.1966787

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

1.  Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.

Authors:  Huan-Chau Lin; Ferry Saputra; Gilbert Audira; Yu-Heng Lai; Marri Jmelou M Roldan; Honeymae C Alos; Charlaine A Aventurado; Ross D Vasquez; Guan-Jhe Tsai; Ken-Hong Lim; Chung-Der Hsiao
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

Review 2.  The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology-When and Why?

Authors:  Agnieszka Kaczmarska; Patrycja Śliwa; Monika Lejman; Joanna Zawitkowska
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

Review 3.  Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.

Authors:  Khalil Saleh; Alexis Fernandez; Florence Pasquier
Journal:  Cancers (Basel)       Date:  2022-04-01       Impact factor: 6.639

Review 4.  Modern Management Options for Ph+ ALL.

Authors:  Josep-Maria Ribera; Sabina Chiaretti
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.